Intuitive announced the clearance of two innovative technologies for two of the company’s da Vinci® surgical systems to help improve procedures that require sealing of tissues and vessels.
Editor's Note: This publication was originally published on Intuitive's website.
SUNNYVALE, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced U.S. Food and Drug Administration clearance of two innovative technologies for two of the company’s da Vinci® surgical systems to help improve procedures that require sealing.
Intuitive’s E-100 generator is its first internally developed robotic generator to power two key instruments on the da Vinci X® and Xi™ systems. Vessel Sealer Extend is the flagship instrument in the da Vinci energy sealing portfolio today, and the new SynchroSeal instrument offers enhanced capabilities1 in general surgery.
We are pleased to receive FDA clearance, providing surgeons an additional tool for the X and Xi da Vinci platforms,” said Bob DeSantis, Intuitive’s Senior Vice President and General Manager for Instruments and Accessories. “We developed SynchroSeal and the E-100 generator to help surgeons quickly seal and transect tissue and vessels, facilitating efficient technique.” Click here to continue>>
News from our Partner
